Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy with Entecavir, PEG-IFN, and Immunomodulators in Chronic Hepatitis B
NCT03332329Phase 4Unknown
- Start
- Dec 2015
- Primary completion
- Dec 2018
- Modality
- Polymer-based Nanoparticles, Split/Subunit Vaccines, Cytokines & Interferons
01
Overview
Phase 4, open-label, single-arm trial of peginterferon alfa-2b, sargramostim and Hepatitis B vaccine in Chronic Hepatitis B (CHB). Primary endpoint: HBsAg loss rate at 108 weeks. Status: unknown.
02
Drugs
peginterferon alfa-2bsargramostimHepatitis B vaccine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03332329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332329.